The effect of teriparatide to alleviate pain and to prevent vertebral collapse after fresh osteoporotic vertebral fracture.

Tsuchie H, Miyakoshi N, Kasukawa Y, Nishi T, Abe H, Segawa T, Shimada Y

Journal of bone and mineral metabolism14 Mar 2015Cited by 43 (Europe PMC)

PMID25773046DOI10.1007/s00774-014-0646-yPepBankPUB-25773046

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialEfficacy outcome
In vertebral fracture patients, daily teriparatide reduced pain scores compared with risedronate at 8 and 12 weeks.
In plain wordsIn vertebral fracture patients, daily teriparatide reduced pain scores compared with risedronate at 8 and 12 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseLow back pain at 8 and 12 weeks
Study
n: not reported in source
Comparator
Risedronate
Outcome group
Pain · Musculoskeletal
Studied dose
20 µg/day dailyAs given in this study (human).
Source sentences
Summary
At 8 and 12 weeks after the initial visit, VAS scores in the Daily and Weekly groups were significantly lower than in the RIS group (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-four patients with fresh vertebral fracture (48 vertebrae) participated in this study.
Summary · context
They were administered either teriparatide (daily 20 µg/day or weekly 56.5 µg/week) or risedronate (17.5 mg/week): ten patients (20 vertebrae) received teriparatide daily (Daily group), 11 patients (15 vertebrae) received teriparatide weekly (Weekly group), and 13 patients (14 vertebrae) received ri…
Report a problemFND-2577304601
02HumanNon-randomized trialEfficacy outcome
In vertebral fracture patients, weekly teriparatide reduced pain scores compared with risedronate at 8 and 12 weeks.
In plain wordsIn vertebral fracture patients, weekly teriparatide reduced pain scores compared with risedronate at 8 and 12 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseLow back pain at 8 and 12 weeks
Study
n: not reported in source
Comparator
Risedronate
Outcome group
Pain · Musculoskeletal
Studied dose
56.5 µg/week weeklyAs given in this study (human).
Source sentences
Summary
At 8 and 12 weeks after the initial visit, VAS scores in the Daily and Weekly groups were significantly lower than in the RIS group (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-four patients with fresh vertebral fracture (48 vertebrae) participated in this study.
Summary · context
They were administered either teriparatide (daily 20 µg/day or weekly 56.5 µg/week) or risedronate (17.5 mg/week): ten patients (20 vertebrae) received teriparatide daily (Daily group), 11 patients (15 vertebrae) received teriparatide weekly (Weekly group), and 13 patients (14 vertebrae) received ri…
Report a problemFND-2577304602
03HumanNon-randomized trialEfficacy outcome
In vertebral fracture patients, daily teriparatide reduced vertebral collapse rates versus risedronate at 8 and 12 weeks.
In plain wordsIn vertebral fracture patients, daily teriparatide reduced vertebral collapse rates versus risedronate at 8 and 12 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseVertebral collapse rate at 8 and 12 weeks
Study
n: not reported in source
Comparator
Risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/day dailyAs given in this study (human).
Source sentences
Summary
At 8 and 12 weeks, the vertebral collapse rate and local kyphotic angle in the Daily group were significantly lower than in the RIS and Control groups (p < 0.01 and p < 0.05, respectively)
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-four patients with fresh vertebral fracture (48 vertebrae) participated in this study.
Summary · context
They were administered either teriparatide (daily 20 µg/day or weekly 56.5 µg/week) or risedronate (17.5 mg/week): ten patients (20 vertebrae) received teriparatide daily (Daily group), 11 patients (15 vertebrae) received teriparatide weekly (Weekly group), and 13 patients (14 vertebrae) received ri…
Report a problemFND-2577304603
04HumanNon-randomized trialEfficacy outcome
In vertebral fracture patients, daily teriparatide reduced vertebral collapse rates versus untreated controls at 8 and 12 weeks.
In plain wordsIn vertebral fracture patients, daily teriparatide reduced vertebral collapse rates versus untreated controls at 8 and 12 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseVertebral collapse rate at 8 and 12 weeks
Study
n: not reported in source
Comparator
No osteoporotic medication
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/day dailyAs given in this study (human).
Source sentences
Summary
At 8 and 12 weeks, the vertebral collapse rate and local kyphotic angle in the Daily group were significantly lower than in the RIS and Control groups (p < 0.01 and p < 0.05, respectively)
3 context sentences(design, population, supporting numbers)
Summary · context
In addition, we evaluated 22 vertebral fracture patients (24 vertebrae) who did not take any osteoporotic medicines (Control group).
Summary · context
Thirty-four patients with fresh vertebral fracture (48 vertebrae) participated in this study.
Summary · context
They were administered either teriparatide (daily 20 µg/day or weekly 56.5 µg/week) or risedronate (17.5 mg/week): ten patients (20 vertebrae) received teriparatide daily (Daily group), 11 patients (15 vertebrae) received teriparatide weekly (Weekly group), and 13 patients (14 vertebrae) received ri…
Report a problemFND-2577304604
05HumanNon-randomized trialEfficacy outcome
In vertebral fracture patients, daily teriparatide reduced local kyphotic angles versus risedronate at 8 and 12 weeks.
In plain wordsIn vertebral fracture patients, daily teriparatide reduced local kyphotic angles versus risedronate at 8 and 12 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseLocal kyphotic angle at 8 and 12 weeks
Study
n: not reported in source
Comparator
Risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/day dailyAs given in this study (human).
Source sentences
Summary
At 8 and 12 weeks, the vertebral collapse rate and local kyphotic angle in the Daily group were significantly lower than in the RIS and Control groups (p < 0.01 and p < 0.05, respectively)
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-four patients with fresh vertebral fracture (48 vertebrae) participated in this study.
Summary · context
They were administered either teriparatide (daily 20 µg/day or weekly 56.5 µg/week) or risedronate (17.5 mg/week): ten patients (20 vertebrae) received teriparatide daily (Daily group), 11 patients (15 vertebrae) received teriparatide weekly (Weekly group), and 13 patients (14 vertebrae) received ri…
Report a problemFND-2577304605
06HumanNon-randomized trialEfficacy outcome
In vertebral fracture patients, daily teriparatide reduced local kyphotic angles versus untreated controls at 8 and 12 weeks.
In plain wordsIn vertebral fracture patients, daily teriparatide reduced local kyphotic angles versus untreated controls at 8 and 12 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseLocal kyphotic angle at 8 and 12 weeks
Study
n: not reported in source
Comparator
No osteoporotic medication
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/day dailyAs given in this study (human).
Source sentences
Summary
At 8 and 12 weeks, the vertebral collapse rate and local kyphotic angle in the Daily group were significantly lower than in the RIS and Control groups (p < 0.01 and p < 0.05, respectively)
3 context sentences(design, population, supporting numbers)
Summary · context
In addition, we evaluated 22 vertebral fracture patients (24 vertebrae) who did not take any osteoporotic medicines (Control group).
Summary · context
Thirty-four patients with fresh vertebral fracture (48 vertebrae) participated in this study.
Summary · context
They were administered either teriparatide (daily 20 µg/day or weekly 56.5 µg/week) or risedronate (17.5 mg/week): ten patients (20 vertebrae) received teriparatide daily (Daily group), 11 patients (15 vertebrae) received teriparatide weekly (Weekly group), and 13 patients (14 vertebrae) received ri…
Report a problemFND-2577304606
07HumanNon-randomized trialEfficacy outcome
In vertebral fracture patients, weekly teriparatide reduced vertebral collapse rates versus untreated controls at 8 and 12 weeks.
In plain wordsIn vertebral fracture patients, weekly teriparatide reduced vertebral collapse rates versus untreated controls at 8 and 12 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseVertebral collapse rate at 8 and 12 weeks
Study
n: not reported in source
Comparator
No osteoporotic medication
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 µg/week weeklyAs given in this study (human).
Source sentences
Summary
At 8 and 12 weeks, the vertebral collapse rate and local kyphotic angle in the Daily group were significantly lower than in the RIS and Control groups (p < 0.01 and p < 0.05, respectively), and those in the Weekly group were significantly lower than in the Control group (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
In addition, we evaluated 22 vertebral fracture patients (24 vertebrae) who did not take any osteoporotic medicines (Control group).
Summary · context
Thirty-four patients with fresh vertebral fracture (48 vertebrae) participated in this study.
Summary · context
They were administered either teriparatide (daily 20 µg/day or weekly 56.5 µg/week) or risedronate (17.5 mg/week): ten patients (20 vertebrae) received teriparatide daily (Daily group), 11 patients (15 vertebrae) received teriparatide weekly (Weekly group), and 13 patients (14 vertebrae) received ri…
Report a problemFND-2577304607
08HumanNon-randomized trialEfficacy outcome
In vertebral fracture patients, weekly teriparatide reduced local kyphotic angles versus untreated controls at 8 and 12 weeks.
In plain wordsIn vertebral fracture patients, weekly teriparatide reduced local kyphotic angles versus untreated controls at 8 and 12 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseLocal kyphotic angle at 8 and 12 weeks
Study
n: not reported in source
Comparator
No osteoporotic medication
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 µg/week weeklyAs given in this study (human).
Source sentences
Summary
At 8 and 12 weeks, the vertebral collapse rate and local kyphotic angle in the Daily group were significantly lower than in the RIS and Control groups (p < 0.01 and p < 0.05, respectively), and those in the Weekly group were significantly lower than in the Control group (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
In addition, we evaluated 22 vertebral fracture patients (24 vertebrae) who did not take any osteoporotic medicines (Control group).
Summary · context
Thirty-four patients with fresh vertebral fracture (48 vertebrae) participated in this study.
Summary · context
They were administered either teriparatide (daily 20 µg/day or weekly 56.5 µg/week) or risedronate (17.5 mg/week): ten patients (20 vertebrae) received teriparatide daily (Daily group), 11 patients (15 vertebrae) received teriparatide weekly (Weekly group), and 13 patients (14 vertebrae) received ri…
Report a problemFND-2577304608
09HumanNon-randomized trialEfficacy outcome
In vertebral fracture patients, daily teriparatide reduced cleft frequency compared with risedronate.
In plain wordsIn vertebral fracture patients, daily teriparatide reduced cleft frequency compared with risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseCleft frequency
Study
n: not reported in source
Comparator
Risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/day dailyAs given in this study (human).
Source sentences
Summary
The cleft frequency in the Daily group was significantly lower than in the RIS group (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-four patients with fresh vertebral fracture (48 vertebrae) participated in this study.
Summary · context
They were administered either teriparatide (daily 20 µg/day or weekly 56.5 µg/week) or risedronate (17.5 mg/week): ten patients (20 vertebrae) received teriparatide daily (Daily group), 11 patients (15 vertebrae) received teriparatide weekly (Weekly group), and 13 patients (14 vertebrae) received ri…
Report a problemFND-2577304609

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.